Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: BRRY) ("DelMar") today announced the successful acquisition (the "Acquisition"), through a share exchange agreement, of all of the outstanding shares of Del Mar Pharmaceuticals (BC) Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer.  Concurrent with the Acquisition, DelMar completed the first closing in a private placement consisting of approximately 6.7 million units of its securities to qualified accredited investors, for total gross proceeds of approximately $5.4 million.

DelMar will be quoted on the OTC QB under the symbol "BRRY" beginning January 25th, 2013; the symbol will be changed to "DMPI" on or about January 31, 2013.

Charles Vista LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant.

"DelMar is pleased to achieve this important milestone," stated Jeffrey Bacha , Chief Executive Officer of DelMar. "Becoming a publicly traded company will allow for broad and diversified investor exposure and access to the capital markets.  These funds will position us to expand and accelerate our drug development activities with our lead drug candidate, VAL-083.  Our company and our management are committed to creating shareholder value by executing on our mission to rapidly develop and commercialize proven cancer therapies in new orphan drug indications in areas of significant unmet medical need, particularly where patients have failed modern targeted medicines."

VAL-083, represents a "first in class" small-molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... HIV detection using INSTI HIV-1/HIV-2 Antibody Test was accepted for presentation at the ... in Vancouver. The results will be presented Wednesday, July 22nd from 1:00 pm ...
(Date:7/7/2015)... , July 7, 2015  Neogen Corporation (NASDAQ: ... an agreement to expand its relationship with Illumina (NASDAQ: ... genomics. Under the agreement, Illumina will market and sell ... Infinium ® BeadArray technology, to the global agrigenomics ... agrigenomic customers through its GeneSeek ® genomics laboratory ...
(Date:7/7/2015)... July 7, 2015   Moleculera Labs ... matching grant from the Oklahoma Center for the ... supports the development and clinical validation of new ... neuronal antigens in patients experiencing neuropsychiatric disorders such ... are intended to assist physicians in identifying the ...
(Date:7/7/2015)... ... , ... The global aptamers market is expected to reach ... of 17.89% between 2015 and 2020. The aptamer type segments included in this ... report is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications ...
Breaking Biology Technology:bioLytical to Present Findings of Early HIV Detection 2bioLytical to Present Findings of Early HIV Detection 3Neogen signs commercialization agreement with Illumina 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 2Moleculera Labs Receives Grant from OCAST to Develop Assays to Identify Individuals with Neuropsychiatric Disorders of Autoimmune Origin 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5
... earnings from continuing operations during the first ... million US dollars ... All amounts in US dollars, QUEBEC CITY, May 6 /PRNewswire-FirstCall/ ... of,added value products for health and nutrition industries, announced today,his financial results ...
... MYERS, Fla., May 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) ... financial results on Wednesday, May 7, 2008., The ... their,Q1 08 results on May 7, 2008, at 11:00 AM ... 689-8565 (international) at least,five minutes prior to the call. ...
... 5 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a,company ... early,detection of diseases and personalized health management, today ... its Board of,Directors, Mr. Harry A. Glorikian and ... James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner Dreismann, ...
Cached Biology Technology:Atrium shows a strong financial performance for its first quarter 2Atrium shows a strong financial performance for its first quarter 3Atrium shows a strong financial performance for its first quarter 4Atrium shows a strong financial performance for its first quarter 5NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2Genenews adds two members to its Board of Directors 2
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/15/2015)... According to a new market ... Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & ... MarketsandMarkets, The Natural Language Processing Market is expected to ... for the forecast period 2015-2020. Browse ... igures spread   through 155 P ages and ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... new spring leaves up to 17 days earlier in the ... rise, according to a new study by Princeton University researchers. ... of northeastern forests and give a boost to their ability ... role in taking up carbon dioxide from the atmosphere, so ...
... reefs build their structures by both producing and accumulating ... and continued vertical growth capacity of reefs. An international ... carbonate being added by Caribbean coral reefs is now ... in some habitats is as much as 70% lower. ...
... have been named Charter Fellows of the National Academy ... and technological innovation. UH faculty members Benton Baugh, ... physics professor and chief scientist of the Texas Center ... professor in chemical and biomedical engineering, are among 101 ...
Cached Biology News:Spring may come earlier to North American forests 2Spring may come earlier to North American forests 3New evidence highlights threat to Caribbean coral reef growth 2New evidence highlights threat to Caribbean coral reef growth 3National Academy of Inventors honors 3 University of Houston professors 2National Academy of Inventors honors 3 University of Houston professors 3
Umbilical cord blood mesenchymal stem cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Progenitor Cells...
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: